神经保护
神经炎症
医学
小胶质细胞
吴茱萸碱
创伤性脑损伤
神经科学
药理学
细胞因子
星形胶质增生
坏死性下垂
神经学
中枢神经系统
肿瘤坏死因子α
麻醉
炎症
白细胞介素6
治疗效果
胶质增生
作者
Huiqin Zheng,Xue-Jun Tian,Wang Yadong,Xiaodi Ye,Xiaoxu Ren,Yangyang Gu,Juehan Wang,Gao-Li ZHeng,Xiao-Feng Yang
标识
DOI:10.1016/j.phrs.2025.108034
摘要
Severe traumatic brain injury (sTBI) lacks effective therapies despite its high morbidity and mortality in young adults. Here, we demonstrate that evodiamine (EVO), a natural alkaloid from Evodia rutaecarpa, significantly improves neurological outcomes in a murine sTBI model (controlled cortical impact). EVO administration (0.3-3.0 mg/kg, intraperitoneal) attenuated cerebral edema, preserved neuronal ultrastructure, and reduced neuroinflammation by suppressing microglial activation and cytokine release. Mechanistically, while EVO showed no direct neuroprotection against H2O2, CoCl2, or oxygen-glucose deprivation-injury in vitro, it significantly enhanced neuronal survival in BV2 microglia-OxyHb co-cultures. Crucially, EVO selectively induced PANoptosis - a coordinated activation of pyroptosis, apoptosis, and necroptosis with PANoptosome formation- in microglia, thereby disrupting their pro-inflammatory activity. This study identifies microglial PANoptosis as the primary therapeutic target of EVO to alleviate post-sTBI neuroinflammation. Our findings position EVO as a promising early-phase intervention for sTBI, offering the first evidence of microglial PANoptosis modulation in neurological therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI